4.5 Review

Nanotherapeutics for pulmonary drug delivery: An emerging approach to overcome respiratory diseases

Journal

Publisher

ELSEVIER
DOI: 10.1016/j.jddst.2023.104261

Keywords

Nanomedicines; Dry powder inhaler; Metered dose inhaler; Nebulizers; Soft mist inhaler; Computational fluid dynamics; Pulmonary drug delivery

Ask authors/readers for more resources

Pulmonary diseases are a significant global health threat. Recent years have seen the emergence of nanotherapeutics-based approaches to tackle these diseases. Nanomedicine can be used to deliver drugs directly into lung tissue via aerosol or dry powder inhalation, targeting deep lung deposition and enhancing therapeutic efficacy. Particle engineering plays a crucial role in developing inhalable formulations that improve drug delivery and targeting effects.
Pulmonary diseases pose an immense threat to global health. Several nanotherapeutics-based approaches aimed to tackle pulmonary ailments in recent years. The current innovation includes developing nanomedicine for pulmonary delivery of active pharmaceutical ingredients, repurposed drugs, host-directed therapies, or molecules with unconventional mechanisms (such as antimicrobial peptides). But pulmonary delivery of nanomedicines is troublesome due to poor aerodynamic properties for lung deposition and expulsion during inhalation. Nanomedicine can deliver drugs directly into lung tissue via aerosol or dry powder for inhalation to target deep lung deposition and subsequent therapeutic efficacy. Particulate-based drug delivery systems are potentially complementary to conventional inhaled drugs. There are several ways to produce an aerosol or DPIbased therapeutics, and we reviewed some standard methods used to develop nanotherapeutics for inhalation. The developed inhalable formulations can be delivered using inhalation devices, and advanced inhaler device technology has allowed the efficacious delivery of therapeutic compounds via inhalation. In addition, particle engineering is a crucial criterion in developing inhalable formulations to improve drug delivery, enhance therapeutic effects, and perform superior targeting. Technological advancements in inhalation devices have improved the efficiency of lung-based drug delivery mechanisms. This review also enumerated the assessment of pulmonary drug delivery systems, i.e., in vitro, ex vivo, in vivo, or in silico models, which have made significant strides in recent years.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available